Based on the above analysis, LY96 and TMEM140 were possible key genes associated with SLE and PD, Drugs targeting these genes may have a greater impact on the occurrence and progression of the diseases, To confirm their mechanism as molecular drugs for treating patients with SLE and PD, We submitted the two genes(LY96 and TMEN140) to the CTD database to screen for promising small molecule compounds that could be used for SLE and PD management. This evidence concerns the gene LY96 and systemic lupus erythematosus.